Table 1.
Baseline characteristics of the study cohort (NOS, not otherwise specified; TILs, tumor infiltrating lymphocytes).
| Number (%) | Number (%) | ||
|---|---|---|---|
| All patients | 1,279 (100) | Mitotic count | |
| Sex | 0-2 | 798 (62.39) | |
| Male | 678 (53.0) | >2 | 252 (19.70) |
| Female | 601 (47.0) | Not known | 229 (17.91) |
| Age (years) | TILs | ||
| <40 | 155 (12.1) | Present | 927 (72.5) |
| 40-49 | 252 (19.7) | Absent | 189 (14.8) |
| 50-59 | 252 (19.7) | Not known | 163 (12.7) |
| 60-69 | 257 (20.1) | Tumor status (T) | |
| 70-79 | 217 (17) | T1 | 820 (64.1) |
| 80+ | 146 (11.4) | T2 | 167 (13.1) |
| Tumor site | T3 | 126 (9.8) | |
| Lower limbs | 260 (20.33) | T4 | 98 (7.7) |
| Upper limbs | 195 (15.25) | TX | 14 (1.1) |
| Head | 133 (10.40) | Not known | 54 (4.2) |
| Hands/feet | 56 (4.38) | Nodal status (N) | |
| Trunk | 593 (46.36) | N0 | 1,119 (87.5) |
| Not known | 42 (3.28) | N1 | 64 (5) |
| Histological subtype | N2 | 45 (3.5) | |
| Superficial spreading melanoma | 926 (72.40) | N3 | 31 (2.4) |
| Nodular melanoma | 159 (12.43) | Not known | 20 (1.6) |
| Lentigo maligna | 28 (2.19) | Metastasis status (M) | |
| Acral-lentiginous melanoma | 25 (1.95) | M0 | 1,225 (95.78) |
| Desmoplastic melanoma | 4 (0.31) | M1 | 26 (2.03) |
| Blue nevus | 1 (0.08) | Not known | 28 (2.19) |
| Spitzoid melanoma | 28 (2.19) | TNM Stage (enrolment) | |
| NOS Malignant melanoma | 34 (2.66) | I | 918 (71.8) |
| Growth phase | II | 161 (12.6) | |
| Horizontal | 285 (22.3) | III | 117 (9.1) |
| Vertical | 701 (54.8) | IV | 26 (2) |
| Not known | 293 (22.9) | Not known | 57 (4,5) |
| Ulceration | Sentinel lymph node (*) | ||
| Yes | 202 (15.8) | Performed | 360 (0.45) |
| No | 1,003 (78.4) | Not performed | 86 (80.35) |
| Not known | 74 (5.8) | Not known | 2 (19.20) |
(*) Only for patients with stage pT1b-pT4b and on stage I-II.